Mednax Down -21% Since Our Analyst's Short Call: What's Next?

05/04/17 11:11AM EDT

Below is an institutional research note written by Hedgeye Healthcare analyst Thomas Tobin and Andrew Freedman. After falling -21% since Mednax was named to the Healthcare team's short list, Tobin and Freedman still see around -25% downside for shares.

Mednax Down -21% Since Our Analyst's Short Call: What's Next? - md 5 4 17

*If you're an institutional investor email sales@hedgeye.com to read Hedgeye's Healthcare research notes.

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.